<PAPER><mode2 name='PMC4276668' hasDoc='yes' version='597'></mode2><article xmlns:mml='http://www.w3.org/1998/Math/MathML' xmlns:xlink='http://www.w3.org/1999/xlink' article-type='research-article'><front><journal-meta><journal-id journal-id-type='nlm-ta'>Neurol Res Int</journal-id><journal-id journal-id-type='iso-abbrev'>Neurol Res Int</journal-id><journal-id journal-id-type='publisher-id'>NRI</journal-id><journal-title-group><journal-title>Neurology Research International</journal-title></journal-title-group><issn pub-type='ppub'>2090-1852</issn><issn pub-type='epub'>2090-1860</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type='pmcid'>4276668</article-id><article-id pub-id-type='doi'>10.1155/2014/423602</article-id><article-categories><subj-group subj-group-type='heading'><subject>Research Article</subject></subj-group></article-categories><title-group><article-title><s sid='1'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>Past Cigarette Smoking Is More Common among Those with Cholinergic Than Noncholinergic Dementias</s></article-title></title-group><contrib-group><contrib contrib-type='author'><name><surname>Dalrymple</surname><given-names>Kyle</given-names></name><xref rid='I1' ref-type='aff'><sup>1</sup></xref></contrib><contrib contrib-type='author'><name><surname>Saito</surname><given-names>Erin K.</given-names></name><xref rid='I2' ref-type='aff'><sup>2</sup></xref></contrib><contrib contrib-type='author'><contrib-id contrib-id-type='orcid'>http://orcid.org/0000-0001-9424-381X</contrib-id><name><surname>Diaz</surname><given-names>Natalie</given-names></name><xref rid='I2' ref-type='aff'><sup>2</sup></xref><xref rid='I3' ref-type='aff'><sup>3</sup></xref><xref rid='I4' ref-type='aff'><sup>4</sup></xref></contrib><contrib contrib-type='author'><name><surname>Morrow</surname><given-names>Julia</given-names></name><xref rid='I4' ref-type='aff'><sup>4</sup></xref></contrib><contrib contrib-type='author'><contrib-id contrib-id-type='orcid'>http://orcid.org/0000-0001-6506-9672</contrib-id><name><surname>Nakamoto</surname><given-names>Beau</given-names></name><xref rid='I5' ref-type='aff'><sup>5</sup></xref><xref rid='I6' ref-type='aff'><sup>6</sup></xref></contrib><contrib contrib-type='author'><name><surname>McMurtray</surname><given-names>Aaron M.</given-names></name><xref rid='I2' ref-type='aff'><sup>2</sup></xref><xref rid='I3' ref-type='aff'><sup>3</sup></xref><xref rid='I4' ref-type='aff'><sup>4</sup></xref><xref rid='cor1' ref-type='corresp'><sup>*</sup></xref></contrib></contrib-group><aff id='I1'><sup>1</sup>Pitzer College, Claremont, CA 91711, USA</aff><aff id='I2'><sup>2</sup>Neurology Division, Los Angeles Biomedical Research Institute, Torrance, CA 90502, USA</aff><aff id='I3'><sup>3</sup>Neurology Department, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-6975, USA</aff><aff id='I4'><sup>4</sup>Neurology Department, Harbor-UCLA Medical Center, Building N-25, 1000 West Carson Street, Torrance, CA 90509, USA</aff><aff id='I5'><sup>5</sup>Neurology Department, Straub Hospital and Clinics, Honolulu, HI 96813, USA</aff><aff id='I6'><sup>6</sup>Neurology Division, Department of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI 96813, USA</aff><author-notes><corresp id='cor1'>*Aaron M. McMurtray: <email>amcmurtray@hotmail.com</email></corresp><fn fn-type='other'><p>Academic Editor: Herbert Brok</p></fn></author-notes><pub-date pub-type='ppub'><year>2014</year></pub-date><pub-date pub-type='epub'><day>10</day><month>12</month><year>2014</year></pub-date><volume>2014</volume><elocation-id>423602</elocation-id><history><date date-type='received'><day>19</day><month>9</month><year>2014</year></date><date date-type='rev-recd'><day>24</day><month>11</month><year>2014</year></date><date date-type='accepted'><day>25</day><month>11</month><year>2014</year></date></history><permissions><copyright-statement>Copyright © 2014 Kyle Dalrymple et al.</copyright-statement><copyright-year>2014</copyright-year><license license-type='open-access'><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><s sid='2'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1><italic>Background</italic>.</s><s sid='3'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Patients with progressive dementing disorders associated with cortical cholinergic dysfunction gradually develop cholinergic deficits many years before symptom onset and may begin to smoke cigarettes during midlife as a form of self-medication.</s><s sid='4'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1> The aim of this study was to compare self-reported past smoking rates between those with and without cholinergic dementias, to determine if those who developed cholinergic dementias were more likely to smoke during midlife than those who did not. <italic>Methods</italic>.</s><s sid='5'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Retrospective cross-sectional study of past smoking status among patients treated at an outpatient clinic during a three-year period. <italic>Results</italic>.</s><s sid='6'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> A total of 440 patients were evaluated during the study period, including 224 with cholinergic dementias and 216 with noncholinergic dementias and controls.</s><s sid='7'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Past smoking rates were greater among those with cholinergic dementias compared to those without cholinergic dementias (43.92% versus 26.96%, <italic>P</italic> = 0.012).</s><s sid='8'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Additionally, smokers with cholinergic dementias reported significantly greater mean pack-years of smoking (<italic>P</italic> = 0.038). <italic>Conclusions</italic>.</s><s sid='9'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Greater midlife smoking rates and greater pack-years of smoking were associated with cholinergic dementias.</s><s sid='10'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> These results suggest midlife smoking may be an early indicator for those developing brain cholinergic deficits related to progressive dementing disorders and support initiating treatment prior to symptom onset in cholinergic dementias.</s></p></abstract></article-meta></front><body><sec id='sec1'><title>1. Introduction</title><p><s sid='11'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Cholinergic dementias, those associated with progressive degeneration of cortical cholinergic neurons such as Alzheimer's disease (AD), dementia in Parkinson's disease (PDD) vascular dementia, and Lewy body dementia (LBD), show symptoms of cognitive decline related to gradually decreasing levels of brain acetylcholine (ACh) [<xref rid='B1' ref-type='bibr'>1</xref>, <xref rid='B2' ref-type='bibr'>2</xref>].</s><s sid='12'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The cortical cholinergic deficit is especially notable in LBD, which may display the largest relative deficit of cortical cholinergic function out of these disorders [<xref rid='B3' ref-type='bibr'>3</xref>, <xref rid='B4' ref-type='bibr'>4</xref>].</s><s sid='13'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In LBD and other cholinergic dementias, there is an inverse relationship between cortical cholinergic function and disease symptoms, with reduced cortical cholinergic function correlating with worsening cognitive deficits and other symptoms [<xref rid='B5' ref-type='bibr'>5</xref>].</s><s sid='14'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> As cortical ACh levels decrease, there is downregulation of postsynaptic AchRs, resulting in further reduction of cortical ACh levels through decreased reuptake and consequently further worsening of cholinergic system functioning [<xref rid='B6' ref-type='bibr'>6</xref>, <xref rid='B7' ref-type='bibr'>7</xref>].</s></p><p><s sid='15'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Cholinesterase inhibitor therapy has long been used in patients with cholinergic dementias as a means of providing symptomatic relief.</s><s sid='16'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> However, treatment with cholinesterase inhibitors does not prevent neuronal loss and has not demonstrated any disease modifying effect.</s><s sid='17'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> It is possible that in order for treatment of these disorders to be effective and change the course of the disease it must be started much earlier, before symptomatic onset and before substantial neuronal degeneration has occurred.</s><s sid='18'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> However, while there have been recent advances with brain amyloid neuroimaging and other potential biomarkers for dementias, there is currently no consensus regarding how to identify potentially at-risk individuals while still young and healthy or the ages at which cortical cholinergic deficits typically begin to occur in these disorders.</s><s sid='19'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Consequently, the optimal ages to begin interventions for these disorders are not yet known.</s></p><p><s sid='20'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Nicotine has been shown to bind and exert its action at nicotinic AChRs (nAChR) in the brain and is considered a nonselective AChR agonist.</s><s sid='21'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Studies have correlated nAChR dysfunction with the neurodegeneration and cognitive deficits of Alzheimer's disease [<xref rid='B8' ref-type='bibr'>8</xref>].</s><s sid='22'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Functional neuroimaging studies have shown that cigarette smoking results in occupancy and upregulation of nAChR in the human brain [<xref rid='B9' ref-type='bibr'>9</xref>, <xref rid='B10' ref-type='bibr'>10</xref>].</s><s sid='23'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Chronic nicotine treatment has shown protection from nAChR synaptic impairments believed to be induced by A<italic>β</italic> oligomers in rat models of Alzheimer's disease and prevention of impaired learning and short-term memory [<xref rid='B11' ref-type='bibr'>11</xref>].</s><s sid='24'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Consequently, nicotine obtained from cigarette smoking may be regarded as a form of unknowingly attempted self-medication when used by those developing cholinergic dementias.</s></p><p><s sid='25'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>Our study was designed to investigate the potential relationship between a history of past cigarette smoking and clinical dementia diagnosis.</s><s sid='26'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> We hypothesized that those with cholinergic dementias would report greater past smoking rates compared to those with noncholinergic dementias and normal controls.</s><s sid='27'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> A greater frequency of past cigarette smoking among those with cholinergic dementias compared to those with noncholinergic dementias would add support to the contention that the cortical cholinergic deficit in cholinergic dementias begins many years earlier in life and also add support for earlier intervention before symptom onset.</s></p></sec><sec id='sec2'><title>2. Materials and Methods</title><sec id='sec2.1'><title>2.1. Participants</title><p><s sid='28'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>This study was determined to be exempt by the local institutional review board since it consisted of a retrospective review of deidentified clinical data.</s><s sid='29'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> Participants were all adults, over the age of 18 years, who presented sequentially to a community based outpatient neurology subspecialty clinic during a three-year period from January 1, 2010, to December 31, 2013, for evaluation and treatment of cognitive problems, dementia, or Parkinson's disease.</s><s sid='30'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> All participants underwent a history and physical examination by a board certified neurologist and dementia diagnoses were determined through retrospective analysis of chart notes according to standard clinical diagnostic criteria.</s></p></sec><sec id='sec2.2'><title>2.2. Determination of Cholinergic and Noncholinergic Dementias</title><p><s sid='31'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>For the purposes of this study participants were divided into two groups based on their clinical diagnosis, one for cholinergic dementia present and one for cholinergic dementia absent.</s><s sid='32'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The group of participants with cholinergic dementia present included those with diagnoses in which a deficit of brain acetylcholine levels has previously been established as part of the underlying neurochemistry of the disorder, such as Alzheimer's disease, dementia in Parkinson's disease, vascular dementia, and Lewy body dementia [<xref rid='B1' ref-type='bibr'>1</xref>, <xref rid='B2' ref-type='bibr'>2</xref>, <xref rid='B4' ref-type='bibr'>4</xref>, <xref rid='B12' ref-type='bibr'>12</xref>, <xref rid='B13' ref-type='bibr'>13</xref>].</s><s sid='33'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The group with cholinergic dementia absent included diagnoses in which brain cholinergic deficits are not considered a prominent feature of the neurochemistry, such as frontotemporal dementia, Parkinson's disease without dementia, and cognitively normal controls [<xref rid='B12' ref-type='bibr'>12</xref>].</s></p></sec><sec id='sec2.3'><title>2.3. Determination of Past Smoking Status</title><p><s sid='34'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>A positive history of past cigarette smoking was determined by retrospective chart review of physician outpatient clinic notes.</s><s sid='35'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> A positive past cigarette smoking status was determined to be present if the patient, caregiver, or family reported the patient smoked cigarettes on a regular basis earlier in life.</s><s sid='36'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Pack-year quantifications of past cigarette smoking were recorded when documented in the chart notes.</s></p></sec><sec id='sec2.4'><title>2.4. Statistical Analysis</title><p><s sid='37'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Participants were divided into two groups for statistical analysis: (1) those with cholinergic dementias and (2) those without cholinergic dementias including those with noncholinergic dementias and cognitively normal controls.</s><s sid='38'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Mean values for continuous demographic factors and other continuous variables, including pack-years of smoking, were compared between groups using two-tailed <italic>t</italic>-tests.</s><s sid='39'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Nonparametric data, including positive or negative past smoking status, were compared between groups using the chi-square test.</s><s sid='40'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> All statistical calculations were performed using SPSS version 22.</s></p></sec></sec><sec id='sec3'><title>3. Results</title><p><s sid='41'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>A total of 440 patients were evaluated during the study period.</s><s sid='42'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> One hundred and thirty-six of these patients were excluded from the study because a reliable past smoking history, either positive or negative, was not documented in the chart notes.</s><s sid='43'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> Past smoking histories were able to be obtained on 304 patients, including 140 with Alzheimer's disease, 16 with dementia with Lewy bodies, 4 with vascular dementia, 21 with frontotemporal dementia, and 29 with dementia in Parkinson's disease, as well as 75 patients with Parkinson's disease without dementia and 19 cognitively normal individuals who presented with memory complaints.</s><s sid='44'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Additional information quantifying past smoking amount in pack-years was able to be obtained from 50 of the 114 smokers (43.86%), including 45 of the 83 smokers with cholinergic dementias (54.22%) and 5 of the 25 smokers with noncholinergic dementias and controls (20.00%).</s></p><p><s sid='45'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>Subjects with cholinergic dementias were significantly older and had a greater mean age of onset compared to those without cholinergic dementias (see <xref rid='tab1' ref-type='table'>Table 1</xref>).</s><s sid='46'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Those with and without cholinergic dementias did not differ significantly for gender distribution (48.15% and 40.00% female, resp.; see <xref rid='tab1' ref-type='table'>Table 1</xref>).</s><s sid='47'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> A positive history of past cigarette smoking was significantly greater among those with cholinergic dementias compared to those without cholinergic dementias (43.92% versus 26.96%, resp.; <italic>P</italic> = 0.012; see <xref rid='tab1' ref-type='table'>Table 1</xref>).</s><s sid='48'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Mean pack-years of cigarette smoking were also significantly greater among those with cholinergic dementias compared to those without cholinergic dementias for those participants who had this data recorded in the chart notes (<italic>P</italic> = 0.038; see <xref rid='tab1' ref-type='table'>Table 1</xref>).</s></p></sec><sec id='sec4'><title>4. Discussion</title><p><s sid='49'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>In this study, we identified an association between presence of cholinergic dementias and a positive history of cigarette smoking, as well as significantly greater pack-years of cigarette smoking among smokers with cholinergic dementias compared to smokers with noncholinergic dementias and normal controls.</s><s sid='50'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Because cortical cholinergic deficits are theorized to develop very gradually over several decades prior to symptom onset in these disorders, it is possible that the greater frequency and pack-year history of smoking may indicate a form of unknowingly attempted self-medication used by these patients to treat symptoms from gradually developing brain cholinergic deficits.</s><s sid='51'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> These findings also suggest that elderly individuals with a positive smoking history who start developing cognitive impairment may be at relatively higher risk for developing cholinergic rather than noncholinergic dementias, although further prospective study in elderly individuals would be needed to determine any predictive value associated with this finding.</s></p><p><s sid='52'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>The relationship between cigarette smoking, AD, and dementia in general is complicated.</s><s sid='53'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In some groups, specifically those with the APOE4 allele, it has been found that smokers have an increased risk for developing dementia and AD [<xref rid='B14' ref-type='bibr'>14</xref>].</s><s sid='54'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Other reports of studies in the general population have also supported cigarette smoking as an important risk factor for both dementia and AD [<xref rid='B15' ref-type='bibr'>15</xref>].</s><s sid='55'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Among those with early signs of AD, smokers are known to have greater rates of brain atrophy than nonsmokers, for both generalized atrophy and specifically atrophy of areas related to development of AD such as the hippocampus [<xref rid='B16' ref-type='bibr'>16</xref>].</s><s sid='56'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> However, high levels of lifetime smoking (&gt;50 pack-years) are reported to have an inverse relationship with other degenerative dementias and are associated with a reduced risk for development of LBD and PD [<xref rid='B17' ref-type='bibr'>17</xref>].</s><s sid='57'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> With Parkinson's disease, the inverse relationship is dose dependent and those with the greatest pack-year histories are the least likely to develop these disorders [<xref rid='B18' ref-type='bibr'>18</xref>].</s></p><p><s sid='58'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>This study has several limitations.</s><s sid='59'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> First, the decision to study an outpatient population rather than an inpatient population may have introduced a selection bias, since smoking is a risk factor for nursing home placement [<xref rid='B19' ref-type='bibr'>19</xref>].</s><s sid='60'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Additionally, because past smoking status and pack-year histories were determined by retrospective chart review of already existing notes, it is possible that smoking histories were actually underreported.</s><s sid='61'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Others have shown that smoking histories are frequently underestimated when assessed from patient chart notes, and it is possible that another mechanism for obtaining smoking histories such as an anonymous questionnaire may have provided a more accurate assessment [<xref rid='B20' ref-type='bibr'>20</xref>].</s><s sid='62'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Also, we were unable to determine the smoking history for many of the patients seen in the clinic because it simply was not documented in the chart notes, raising the possibility of a reporting bias.</s><s sid='63'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> However, all three of these potential biases would be expected to have affected both groups equally, so we feel that overall the results are relatively reliable.</s><s sid='64'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> Further study of other community and research center populations using anonymous questionnaires to determine smoking histories would be warranted.</s></p></sec><sec id='sec5'><title>5. Conclusions</title><p><s sid='65'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>The results of this study suggest that patients with cholinergic dementias may have greater past cigarette smoking rates than those with noncholinergic dementias and controls.</s><s sid='66'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> It is possible that the nicotine in cigarettes may act as a form of self-medication for people who are gradually developing a cortical cholinergic deficit.</s><s sid='67'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> Additional research focusing on the role of nicotinic AchRs in the development and progression of Alzheimer's disease and other cholinergic dementias is indicated.</s><s sid='68'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> Additionally, future research to identify nicotinic AchR mediated treatments may help to reduce the severity of symptoms patients face as cholinergic dementias progress and may even have the potential for disease modifying effects.</s></p></sec></body><back><sec sec-type='conflict'><title>Conflict of Interests</title><p>The authors declare they have no conflict of interests regarding publication of this paper.</p></sec><ref-list><ref id='B1'><label>1</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Corey-Bloom</surname><given-names>J.</given-names></name></person-group><article-title>The ABC of Alzheimer's disease: cognitive changes and their management in Alzheimer's disease and related dementias</article-title><source><italic>International Psychogeriatrics</italic></source><year>2002</year><volume>14</volume><issue>supplement 1</issue><fpage>51</fpage><lpage>75</lpage><pub-id pub-id-type='doi'>10.1017/S1041610203008664</pub-id><pub-id pub-id-type='other'>2-s2.0-0036990186</pub-id><pub-id pub-id-type='pmid'>12636180</pub-id></element-citation></ref><ref id='B2'><label>2</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Perry</surname><given-names>E. K.</given-names></name><name><surname>Tomlinson</surname><given-names>B. E.</given-names></name><name><surname>Blessed</surname><given-names>G.</given-names></name><name><surname>Bergmann</surname><given-names>K.</given-names></name><name><surname>Gibson</surname><given-names>P. H.</given-names></name><name><surname>Perry</surname><given-names>R. H.</given-names></name></person-group><article-title>Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia</article-title><source><italic>British Medical Journal</italic></source><year>1978</year><volume>2</volume><issue>6150</issue><fpage>1457</fpage><lpage>1459</lpage><pub-id pub-id-type='doi'>10.1136/bmj.2.6150.1457</pub-id><pub-id pub-id-type='other'>2-s2.0-0018078940</pub-id><pub-id pub-id-type='pmid'>719462</pub-id></element-citation></ref><ref id='B3'><label>3</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>McKeith</surname><given-names>I.</given-names></name><name><surname>O'Brien</surname><given-names>J.</given-names></name></person-group><article-title>Dementia with Lewy bodies</article-title><source><italic>The Australian and New Zealand Journal of Psychiatry</italic></source><year>1999</year><volume>33</volume><issue>6</issue><fpage>800</fpage><lpage>808</lpage><pub-id pub-id-type='doi'>10.1046/j.1440-1614.1999.00650.x</pub-id><pub-id pub-id-type='other'>2-s2.0-0033380247</pub-id><pub-id pub-id-type='pmid'>10619205</pub-id></element-citation></ref><ref id='B4'><label>4</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Tiraboschi</surname><given-names>P.</given-names></name><name><surname>Hansen</surname><given-names>L. A.</given-names></name><name><surname>Alford</surname><given-names>M.</given-names></name><name><surname>Sabbagh</surname><given-names>M. N.</given-names></name><name><surname>Schoos</surname><given-names>B.</given-names></name><name><surname>Masliah</surname><given-names>E.</given-names></name><name><surname>Thal</surname><given-names>L. J.</given-names></name><name><surname>Corey-Bloom</surname><given-names>J.</given-names></name></person-group><article-title>Cholinergic dysfunction in diseases with LEWY bodies</article-title><source><italic>Neurology</italic></source><year>2000</year><volume>54</volume><issue>2</issue><fpage>407</fpage><lpage>411</lpage><pub-id pub-id-type='doi'>10.1212/WNL.54.2.407</pub-id><pub-id pub-id-type='other'>2-s2.0-0034711764</pub-id><pub-id pub-id-type='pmid'>10668703</pub-id></element-citation></ref><ref id='B5'><label>5</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>McKeith</surname><given-names>I. G.</given-names></name><name><surname>Grace</surname><given-names>J. B.</given-names></name><name><surname>Walker</surname><given-names>Z.</given-names></name><name><surname>Byrne</surname><given-names>E. J.</given-names></name><name><surname>Wilkinson</surname><given-names>D.</given-names></name></person-group><article-title>Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial</article-title><source><italic>International Journal of Geriatric Psychiatry</italic></source><year>2000</year><volume>15</volume><issue>5</issue><fpage>387</fpage><lpage>392</lpage><pub-id pub-id-type='pmid'>10822236</pub-id></element-citation></ref><ref id='B6'><label>6</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Flynn</surname><given-names>D. D.</given-names></name><name><surname>Ferrari-DiLeo</surname><given-names>G.</given-names></name><name><surname>Mash</surname><given-names>D. C.</given-names></name><name><surname>Levey</surname><given-names>A. I.</given-names></name></person-group><article-title>Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease</article-title><source><italic>Journal of Neurochemistry</italic></source><year>1995</year><volume>64</volume><issue>4</issue><fpage>1888</fpage><lpage>1891</lpage><pub-id pub-id-type='other'>2-s2.0-0028924664</pub-id><pub-id pub-id-type='pmid'>7891119</pub-id></element-citation></ref><ref id='B7'><label>7</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Guan</surname><given-names>Z.-Z.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Ravid</surname><given-names>R.</given-names></name><name><surname>Nordberg</surname><given-names>A.</given-names></name></person-group><article-title>Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease</article-title><source><italic>Journal of Neurochemistry</italic></source><year>2000</year><volume>74</volume><issue>1</issue><fpage>237</fpage><lpage>243</lpage><pub-id pub-id-type='doi'>10.1046/j.1471-4159.2000.0740237.x</pub-id><pub-id pub-id-type='other'>2-s2.0-0033983966</pub-id><pub-id pub-id-type='pmid'>10617125</pub-id></element-citation></ref><ref id='B8'><label>8</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Brody</surname><given-names>A. L.</given-names></name><name><surname>Mandelkern</surname><given-names>M. A.</given-names></name><name><surname>London</surname><given-names>E. D.</given-names></name><name><surname>Olmstead</surname><given-names>R. E.</given-names></name><name><surname>Farahi</surname><given-names>J.</given-names></name><name><surname>Scheibal</surname><given-names>D.</given-names></name><name><surname>Jou</surname><given-names>J.</given-names></name><name><surname>Allen</surname><given-names>V.</given-names></name><name><surname>Tiongson</surname><given-names>E.</given-names></name><name><surname>Chefer</surname><given-names>S. I.</given-names></name><name><surname>Koren</surname><given-names>A. O.</given-names></name><name><surname>Mukhin</surname><given-names>A. G.</given-names></name></person-group><article-title>Cigarette smoking saturates brain <italic>α</italic>4<italic>β</italic>2 nicotinic acetylcholine receptors</article-title><source><italic>Archives of General Psychiatry</italic></source><year>2006</year><volume>63</volume><issue>8</issue><fpage>907</fpage><lpage>915</lpage><pub-id pub-id-type='other'>2-s2.0-33746922400</pub-id><pub-id pub-id-type='doi'>10.1001/archpsyc.63.8.907</pub-id><pub-id pub-id-type='pmid'>16894067</pub-id></element-citation></ref><ref id='B9'><label>9</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Nashmi</surname><given-names>R.</given-names></name><name><surname>Dickenson</surname><given-names>M. E.</given-names></name><name><surname>McKinney</surname><given-names>S.</given-names></name><etal></etal></person-group><article-title>Assembly of alpha-4beta2 nicotinic acetylcholine receptors assessed with functional fluorescently labeled subunits: effects of localization, trafficking and nicotine-induced upregulation in clonal mammalian cells in cultered midbrain neurons</article-title><source><italic>The Journal of Neuroscience</italic></source><year>2003</year><volume>23</volume><issue>37</issue><fpage>11554</fpage><lpage>11567</lpage><pub-id pub-id-type='pmid'>14684858</pub-id></element-citation></ref><ref id='B10'><label>10</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Staley</surname><given-names>J. K.</given-names></name><name><surname>Krishnan-Sarin</surname><given-names>S.</given-names></name><name><surname>Cosgrove</surname><given-names>K. P.</given-names></name><name><surname>Krantzler</surname><given-names>E.</given-names></name><name><surname>Frohlich</surname><given-names>E.</given-names></name><name><surname>Perry</surname><given-names>E.</given-names></name><name><surname>Dubin</surname><given-names>J. A.</given-names></name><name><surname>Estok</surname><given-names>K.</given-names></name><name><surname>Brenner</surname><given-names>E.</given-names></name><name><surname>Baldwin</surname><given-names>R. M.</given-names></name><name><surname>Tamagnan</surname><given-names>G. D.</given-names></name><name><surname>Seibyl</surname><given-names>J. P.</given-names></name><name><surname>Jatlow</surname><given-names>P.</given-names></name><name><surname>Picciotto</surname><given-names>M. R.</given-names></name><name><surname>London</surname><given-names>E. D.</given-names></name><name><surname>O'Malley</surname><given-names>S.</given-names></name><name><surname>Van Dyck</surname><given-names>C. H.</given-names></name></person-group><article-title>Human tobacco smokers in early abstinence have higher levels of <italic>β</italic><sub>2</sub>* nicotinic acetylcholine receptors than nonsmokers</article-title><source><italic>The Journal of Neuroscience</italic></source><year>2006</year><volume>26</volume><issue>34</issue><fpage>8707</fpage><lpage>8714</lpage><pub-id pub-id-type='doi'>10.1523/JNEUROSCI.0546-06.2006</pub-id><pub-id pub-id-type='other'>2-s2.0-33748282547</pub-id><pub-id pub-id-type='pmid'>16928859</pub-id></element-citation></ref><ref id='B11'><label>11</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Srivareerat</surname><given-names>M.</given-names></name><name><surname>Tran</surname><given-names>T. T.</given-names></name><name><surname>Salim</surname><given-names>S.</given-names></name><name><surname>Aleisa</surname><given-names>A. M.</given-names></name><name><surname>Alkadhi</surname><given-names>K. A.</given-names></name></person-group><article-title>Chronic nicotine restores normal A<italic>β</italic> levels and prevents short-term memory and E-LTP impairment in A<italic>β</italic> rat model of Alzheimer's disease</article-title><source><italic>Neurobiology of Aging</italic></source><year>2011</year><volume>32</volume><issue>5</issue><fpage>834</fpage><lpage>844</lpage><pub-id pub-id-type='doi'>10.1016/j.neurobiolaging.2009.04.015</pub-id><pub-id pub-id-type='other'>2-s2.0-79954594758</pub-id><pub-id pub-id-type='pmid'>19464074</pub-id></element-citation></ref><ref id='B12'><label>12</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Kadir</surname><given-names>A.</given-names></name><name><surname>Nordberg</surname><given-names>A.</given-names></name></person-group><article-title>Target-specific PET probes for neurodegenerative disorders related to dementia</article-title><source><italic>Journal of Nuclear Medicine</italic></source><year>2010</year><volume>51</volume><issue>9</issue><fpage>1418</fpage><lpage>1430</lpage><pub-id pub-id-type='doi'>10.2967/jnumed.110.077164</pub-id><pub-id pub-id-type='other'>2-s2.0-77957072855</pub-id><pub-id pub-id-type='pmid'>20810758</pub-id></element-citation></ref><ref id='B13'><label>13</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>H. Y.</given-names></name><name><surname>Tang</surname><given-names>X. C.</given-names></name></person-group><article-title>Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment</article-title><source><italic>Acta Pharmacologica Sinica</italic></source><year>2009</year><volume>30</volume><issue>7</issue><fpage>879</fpage><lpage>888</lpage><pub-id pub-id-type='doi'>10.1038/aps.2009.82</pub-id><pub-id pub-id-type='other'>2-s2.0-67651166807</pub-id><pub-id pub-id-type='pmid'>19574993</pub-id></element-citation></ref><ref id='B14'><label>14</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Ott</surname><given-names>A.</given-names></name><name><surname>Slooter</surname><given-names>A. J. C.</given-names></name><name><surname>Hofman</surname><given-names>A.</given-names></name><name><surname>Van Harskamp</surname><given-names>F.</given-names></name><name><surname>Witteman</surname><given-names>J. C. M.</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C.</given-names></name><name><surname>Van Duijn</surname><given-names>C. M.</given-names></name><name><surname>Breteler</surname><given-names>M. M. B.</given-names></name></person-group><article-title>Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study</article-title><source><italic>The Lancet</italic></source><year>1998</year><volume>351</volume><issue>9119</issue><fpage>1840</fpage><lpage>1843</lpage><pub-id pub-id-type='doi'>10.1016/S0140-6736(97)07541-7</pub-id><pub-id pub-id-type='other'>2-s2.0-0032551222</pub-id></element-citation></ref><ref id='B15'><label>15</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Ho</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Yeung</surname><given-names>S.</given-names></name><etal></etal></person-group><article-title>Cigarette smoking accelerated brain aging and induced pre-alzheimer-like neuropathology in rats</article-title><source><italic>PLoS ONE</italic></source><year>2012</year><volume>7</volume><issue>5</issue><pub-id pub-id-type='publisher-id'>e36752</pub-id><pub-id pub-id-type='doi'>10.1371/journal.pone.0036752</pub-id></element-citation></ref><ref id='B16'><label>16</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Durazzo</surname><given-names>T. C.</given-names></name><name><surname>Insel</surname><given-names>P. S.</given-names></name><name><surname>Weiner</surname><given-names>M. W.</given-names></name></person-group><article-title>Greater regional brain atrophy rate in healthy elderly subjects with a history of cigarette smoking</article-title><source><italic>Alzheimer's &amp; Dementia</italic></source><year>2012</year><volume>8</volume><issue>6</issue><fpage>513</fpage><lpage>519</lpage><pub-id pub-id-type='doi'>10.1016/j.jalz.2011.10.006</pub-id><pub-id pub-id-type='other'>2-s2.0-84867881424</pub-id></element-citation></ref><ref id='B17'><label>17</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Gorell</surname><given-names>J. M.</given-names></name><name><surname>Rybicki</surname><given-names>B. A.</given-names></name><name><surname>Johnson</surname><given-names>C. C.</given-names></name><name><surname>Peterson</surname><given-names>E. L.</given-names></name></person-group><article-title>Smoking and Parkinson's disease: a dose-response relationship</article-title><source><italic>Neurology</italic></source><year>1999</year><volume>52</volume><issue>1</issue><fpage>116</fpage><lpage>119</lpage><pub-id pub-id-type='doi'>10.1212/WNL.52.1.115</pub-id><pub-id pub-id-type='other'>2-s2.0-0032947305</pub-id></element-citation></ref><ref id='B18'><label>18</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Hernán</surname><given-names>M. A.</given-names></name><name><surname>Zhang</surname><given-names>S. M.</given-names></name><name><surname>Rueda-DeCastro</surname><given-names>A. M.</given-names></name><name><surname>Colditz</surname><given-names>G. A.</given-names></name><name><surname>Speizer</surname><given-names>F. E.</given-names></name><name><surname>Ascherio</surname><given-names>A.</given-names></name></person-group><article-title>Cigarette smoking and the incidence of Parkinson's disease in two prospective studies</article-title><source><italic>Annals of Neurology</italic></source><year>2001</year><volume>50</volume><issue>6</issue><fpage>780</fpage><lpage>786</lpage><pub-id pub-id-type='other'>2-s2.0-0035203858</pub-id><pub-id pub-id-type='doi'>10.1002/ana.10028</pub-id><pub-id pub-id-type='pmid'>11761476</pub-id></element-citation></ref><ref id='B19'><label>19</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Wang</surname><given-names>J. J.</given-names></name><name><surname>Mitchell</surname><given-names>P.</given-names></name><name><surname>Smith</surname><given-names>W.</given-names></name><name><surname>Cumming</surname><given-names>R. G.</given-names></name><name><surname>Leeder</surname><given-names>S. R.</given-names></name></person-group><article-title>Incidence of nursing home placement in a defined community</article-title><source><italic>Medical Journal of Australia</italic></source><year>2001</year><volume>174</volume><issue>6</issue><fpage>271</fpage><lpage>275</lpage><pub-id pub-id-type='other'>2-s2.0-0035911214</pub-id><pub-id pub-id-type='pmid'>11297113</pub-id></element-citation></ref><ref id='B20'><label>20</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Havard</surname><given-names>A.</given-names></name><name><surname>Jorm</surname><given-names>L. R.</given-names></name><name><surname>Lujic</surname><given-names>S.</given-names></name></person-group><article-title>Risk adjustment for smoking identified through tobacco use diagnoses in hospital data: a validation study</article-title><source><italic>PLoS ONE</italic></source><year>2014</year><volume>9</volume><issue>4</issue><pub-id pub-id-type='publisher-id'>e95029</pub-id><pub-id pub-id-type='doi'>10.1371/journal.pone.0095029</pub-id><pub-id pub-id-type='other'>2-s2.0-84899683215</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap orientation='portrait' id='tab1' position='float'><label>Table 1</label><caption><p>Comparison of demographic and past smoking history information between those with and without cholinergic dementias.</p></caption><table rules='groups' frame='hsides'><thead><tr><th colspan='1' rowspan='1' align='left'> </th><th colspan='1' rowspan='1' align='center'>Cholinergic dementia present, <italic>n</italic> = 189</th><th colspan='1' rowspan='1' align='center'>Cholinergic dementia absent, <italic>n</italic> = 115</th><th colspan='1' rowspan='1' align='center'>Sig.</th></tr></thead><tbody><tr><td colspan='1' rowspan='1' align='left'>Mean age at visit in years</td><td colspan='1' rowspan='1' align='center'>73.17 (S.D. = 12.32)</td><td colspan='1' rowspan='1' align='center'>69.79 (S.D. = 13.26)</td><td colspan='1' rowspan='1' align='center'><bold>P</bold> = 0.032</td></tr><tr><td colspan='1' rowspan='1' align='left'>Mean onset age in years</td><td colspan='1' rowspan='1' align='center'>60.49 (S.D. = 11.58), </td><td colspan='1' rowspan='1' align='center'>50.96 (S.D. = 13.22)</td><td colspan='1' rowspan='1' align='center'><bold>P</bold> = 0.004</td></tr><tr><td colspan='1' rowspan='1' align='left'>Gender (% female)</td><td colspan='1' rowspan='1' align='center'>48.15%, <italic>n</italic> = 91</td><td colspan='1' rowspan='1' align='center'>40.00%, <italic>n</italic> = 46</td><td colspan='1' rowspan='1' align='center'><italic>P</italic> = 0.299</td></tr><tr><td colspan='1' rowspan='1' align='left'>Positive past smoking history</td><td colspan='1' rowspan='1' align='center'>43.92%, <italic>n</italic> = 83</td><td colspan='1' rowspan='1' align='center'>26.96%, <italic>n</italic> = 31</td><td colspan='1' rowspan='1' align='center'><bold>P</bold> = 0.012</td></tr><tr><td colspan='1' rowspan='1' align='left'>Mean pack-years smoked</td><td colspan='1' rowspan='1' align='center'>52.53 (S.D. = 45.56)</td><td colspan='1' rowspan='1' align='center'>26.80 (S.D. = 18.94)</td><td colspan='1' rowspan='1' align='center'><bold>P</bold> = 0.038</td></tr></tbody></table></table-wrap></floats-group></article></PAPER>